Active Pharmaceutical Ingredients Manufacturing: Emerging Trends, On-Going Innovations & It's Benefits to the Global Pharma Industry

Market growth is driven by the increasing incidence of chronic diseases, rising prevalence of cancer, technological advancements in API manufacturing, growing importance of generics, rapidly increasing geriatric population, increase in abbreviated new drug applications (ANDA) and increasing uptake of biopharmaceuticals.

Furthermore, emerging biosimilars market, increasing scope for HPAPIs, emerging markets and emerging technologies have opened an array of opportunities for the growth of the market. However, factors such as stringent regulatory requirements and unfavorable drug price control policies across various countries may restrain the growth of this market.

Download the PDF Brochure@ https://www.marketsandmarkets.com/pdfdownload.asp?id=263

Opportunities:

# Emerging Biosimilars Market

# Increasing Scope for High-Potency Active Pharmaceutical Ingredients

# Emerging Markets

# Emerging Technologies

Challenges:

# Product Differentiation

# High Manufacturing Costs

-:Industry Segmentation:-

On the basis of type, the active pharmaceutical ingredients market is segmented into innovative and generic APIs. The innovative APIs segment is estimated to command the largest share in 2016. Some of the major factors contributing to its large share include growing demand for innovative therapeutics for treatment of dreadful diseases, especially cancer, the increase in the number of FDA approvals for new molecular entities and the higher prices of innovative APIs (as compared to generics). On the basis of type of manufacturer, the active pharmaceutical ingredients market is segmented into captive and merchant API manufacturers.

The APIs market, on the basis of type of synthesis, is segmented into synthetic and biotech APIs. Synthetic APIs is estimated to dominate this market in 2016.The large share of this segment can be attributed to the emergence of new synthetic molecules in the market, increasing number of new product approvals, less complex manufacturing and approval processes as compared to biologics and technological advancements in the method of synthesis. 

Based on product, the biotech active pharmaceutical ingredients market is segmented into monoclonal antibodies, hormones, vaccines, cytokines, fusion proteins, therapeutic enzymes, and blood factors.

North America dominates the active pharmaceutical ingredients market, with the U.S. accounting for the major share. This can be attributed to the increase in the increasing incidence of chronic diseases, increasing focus of the government on the growing adoption of generic drugs, rising demand for biologics and specialty drugs, and technological advances in API manufacturing in this region.

The prominent players in the active pharmaceutical ingredients market are Pfizer, Inc. (U.S.), Novartis International AG (Switzerland), Sanofi (France), Boehringer Ingelheim (Germany), Bristol-Myers Squibb (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Eli Lilly and Company (U.S.), GlaxoSmithKline plc (U.K.), Merck & Co., Inc. (U.S.) and AbbVie Inc. (U.S.).

Read the Detailed Article@ https://www.marketsandmarkets.com/Market-Reports/API-Market-263.html

Market Stakeholders:

• Medical image management software providers
• Diagnostic imaging equipment vendors/service providers
• Standalone image management software/workstation providers
• Healthcare IT service providers
• Research and consulting firms
• Diagnostic imaging centers
• Hospitals
• Venture capitalists
• Government agencies
• Market research and consulting firms